TITLE

Adjunctive treatment with eplerenone reduced 30-day all-cause mortality in acute myocardial infarction: COMMENTARY

AUTHOR(S)
Moyer, Carey D.; Berger, Peter B.
PUB. DATE
January 2006
SOURCE
ACP Journal Club;Jan/Feb2006, Vol. 144 Issue 1, p15
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This article comments on the clinical trial EPHESUS, according to which adjunctive treatment with eplerenone reduced 30-day all-cause mortality in acute myocardial infarction (MI). Based largely on this trial, the U.S. Food and Drug Administration approved eplerenone in October 2003 for use in patients with congestive heart failure after acute MI. However, if the benefits of eplerenone are to be realized in clinical practice, hyperkalemia ought to be looked for as diligently as it was in the trial. Given the large clinical benefit derived within even 30 days, the question arises whether eplerenone might be beneficial if started even earlier than 3 to 14 days after MI. A cost-effectiveness analysis from EPHESUS showed that the increased survival of patients treated with eplerenone cost $1391 during the 16-month follow-up.
ACCESSION #
19516000

 

Related Articles

  • Stem Cells for Myocardial Regeneration. Penn, M. S.; Dong, F.; Klein, S.; Mayorga, M. E. // Clinical Pharmacology & Therapeutics;Oct2011, Vol. 90 Issue 4, p499 

    The field of cardiovascular regenerative medicine has made significant strides over the past decade. Clinical trials have demonstrated benefit in acute myocardial infarction (AMI) and chronic heart failure (CHF). As the field has matured, it has defined novel biology and invented an array of...

  • Why do we still need large scale clinical trial: the case of n-3 PUFA. Marchioli, Roberto; Levantesi, Giacomo // Frontiers in Physiology;Jun2012, Vol. 3, p1 

    After the first reports about a protective effect on coronary heart disease (CHD) published more than 40 years ago, wide interest in the therapeutic use of n-3 polyunsaturated fatty acids (n-3 PUFA) aroused. Since then, many studies and meta-analyses have reported a significantly reduced risk of...

  • The Patented Uses of D-Ribose in Cardiovascular Diseases. Shecterle, Linda M.; Terry, Kathleen R.; St. Cyr, John A. // Recent Patents on Cardiovascular Drug Discovery;Jun2010, Vol. 5 Issue 2, p138 

    Cardiovascular diseases account for more deaths worldwide than any other illness. Myocardial ischemia, a common finding in cardiovascular diseases, lowers cellular energy levels, which affects a cell's integrity and function. Pre-clinical animal studies have reported lower cellular energy levels...

  • Benefits of exercise therapy for chronic diseases. Kujala, U. M. // British Journal of Sports Medicine;Jan2006, Vol. 40 Issue 1, p3 

    The article focuses on the benefits of exercise therapy for chronic diseases. There is accumulating evidence, on the basis of a recent review of the results of randomised controlled trials (RCTs), that, in patients with chronic disease, exercise therapy is effective in increasing fitness and...

  • Heart Failure. Stevens, Lise M.; Lynm, Cassio; Glass, Richard M. // JAMA: Journal of the American Medical Association;2/6/2002, Vol. 287 Issue 5, p676 

    Presents information about heart failure, a chronic condition in which a diseased heart decreases a person's ability to be physically active. Symptoms of heart failure, including shortness of breath, tiredness, or weakness; Causes of heart failure, including coronary artery disease and...

  • Prevention of sudden cardiac death. Chow, Theodore // Cincinnati Magazine;Nov2004, Vol. 38 Issue 2, special section p6 

    This article focuses on the prevention of sudden cardiac death. More people die from sudden cardiac arrest in the U.S. than from strokes, breast cancer and lung cancer combined. For patients with coronary artery disease, preventing a heart attack is a physician's primary concern. Cardiac arrest...

  • Trial Scorecards.  // Cardiology Today;Sep2010, Vol. 13 Issue 9, p17 

    The article presents summaries of the results available for certain cardiology trials including the Randomized Trial of Phone Intervention in Chronic Heart Failure, Women's Ischemia Syndrome Evaluation and Asymptomatic Carotid Emboli Study.

  • Validation of an echocardiographic wall motion index in heart failure due to ischaemic heart disease. McGowan, J.H.; Martin, W.; Burgess, M.I.; McCurrach, G.; Ray, S.G.; McDonagh, T.A.; Cleland, J.G.F. // European Journal of Heart Failure;Dec2001, Vol. 3 Issue 6, p731 

    Aims:: the echocardiographic assessment of left ventricular ejection fraction (LVEF) by geometric methods is limited in many patients because of inadequate views and also in the presence of regional wall motion abnormalities due to ischaemic heart disease (IHD). This study aimed to examine the...

  • Infarct healing is a dynamic process following acute myocardial infarction. Pokorney, Sean D.; Rodriguez, Jos‚ F.; Ortiz, Jos‚ T.; Lee, Daniel C.; Bonow, Robert O.; Wu, Edwin // Journal of Cardiovascular Magnetic Resonance (BioMed Central);2012, Vol. 14 Issue 1, p62 

    Background: The role of infarct size on left ventricular (LV) remodeling in heart failure after an acute ST-segment elevation myocardial infarction (STEMI) is well recognized. Infarct size, as determined by cardiovascular magnetic resonance (CMR), decreases over time. The amount, rate, and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics